Holen Sie sich die Stockscreener-App
85.27
0.15%
-0.13
Handel nachbörslich:
83.57
-1.70
-1.99%
Schlusskurs vom Vortag:
$85.40
Offen:
$84.59
24-Stunden-Volumen:
433.96K
Relative Volume:
0.57
Marktkapitalisierung:
$6.96B
Einnahmen:
$39.21M
Nettoeinkommen (Verlust:
$-311.35M
KGV:
-23.18
EPS:
-3.6793
Netto-Cashflow:
$-234.34M
1W Leistung:
+7.28%
1M Leistung:
+2.13%
6M Leistung:
+48.17%
1J Leistung:
+286.36%
1-Tages-Spanne:
$83.53
$86.07
1-Wochen-Bereich:
$80.20
$86.78
52-Wochen-Spanne:
$19.45
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
85.27 | 6.97B | 39.21M | -311.35M | -234.34M | -3.6793 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | Fortgesetzt | Guggenheim | Buy |
| 2025-10-24 | Bestätigt | B. Riley Securities | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Kymera Therapeutics Soars After Multiple Analyst Upgrades; Retail Sentiment Turns Extremely Bullish - MSN
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - AOL.com
Kymera Therapeutics (KYMR) to present Phase 1b BroADen trial data for KT-621 at AAD 2026 - MSN
Jeremy Chadwick Sells 7,600 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - marketbeat.com
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $1,251,134.40 in Stock - marketbeat.com
Kymera Therapeutics (NASDAQ:KYMR) Director Sells $631,738.00 in Stock - marketbeat.com
Kymera Therapeutics (NASDAQ:KYMR) Director Elena Ridloff Sells 4,600 Shares - marketbeat.com
Kymera Therapeutics COO sells $1.9 million in shares By Investing.com - Investing.com Canada
Kymera (KYMR) COO sells 22,240 shares after exercising options - stocktitan.net
KYMR (NASDAQ) director/insider plans 4,600-share option exercise; prior 7,400-share 10b5-1 sale - stocktitan.net
Form 144 and 10b5-1 sales reported for KYMR (NASDAQ: KYMR) - stocktitan.net
Kymera's eczema drug gets fast track designation in the United States - MSN
Layoff Watch: What are Kymera Therapeutics Incs earnings expectationsBear Alert & Free Verified High Yield Trade Plans - baoquankhu1.vn
[144] Kymera Therapeutics, Inc. SEC Filing - stocktitan.net
Behavioral Patterns of KYMR and Institutional Flows - Stock Traders Daily
Aug Volume: Is Kymera Therapeutics Inc forming a bullish divergence2026 Geopolitical Influence & Fast Moving Stock Watchlists - baoquankhu1.vn
Does Positive KT-621 Atopic Dermatitis Data Change The Bull Case For Kymera Therapeutics (KYMR)? - Yahoo Finance
Kymera Therapeutics Updates Bylaws on Federal Securities Litigation - TipRanks
JPMorgan Chase & Co. Lowers Stock Position in Kymera Therapeutics, Inc. $KYMR - marketbeat.com
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology Annual Meeting - Investing News Network
Kymera Therapeutics Reports Positive Phase 1b Results for KT-621 in Atopic Dermatitis at AAD Annual Meeting - Quiver Quantitative
Once-daily KT-621 cut dermatitis severity 63% in early trial - Stock Titan
Kymera Therapeutics, Inc. Amends Bylaws and Confirms Common Stock Registration on Nasdaq – SEC 8-K Filing March 2026 - Minichart
Aug PreEarnings: Can Kymera Therapeutics Inc weather a recessionWeekly Loss Report & Safe Entry Point Identification - baoquankhu1.vn
Kymera Therapeutics (KYMR) sets federal courts as exclusive forum for securities claims - stocktitan.net
Vanguard Group (NYSE: V) reports 0 KYMR shares after realignment - Stock Titan
Hedge Fund and Insider Trading News: Catherine Wood, Ray Dalio, Bill Ackman, Warren Buffett, Two Sigma Advisors, MGM Resorts International (MGM), Kymera Therapeutics Inc (KYMR), and More - Insider Monkey
VIX Spike: Will Kymera Therapeutics Inc be affected by tariffs2026 Reactions & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Kymera Therapeutics (NASDAQ:KYMR) COO Sells $7,063,662.50 in Stock - MarketBeat
Jeremy Chadwick Sells 24,727 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Kymera Therapeutics (KYMR) COO sells 115,977 shares after option exercise - stocktitan.net
Kymera Therapeutics (NASDAQ:KYMR) Shares Up 8.4%What's Next? - marketbeat.com
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Analysts - marketbeat.com
KYMR (NASDAQ) insider 10b5-1 sales and option exercise reported - Stock Titan
Hudson Bay Capital Management LP Grows Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
A Look At Kymera Therapeutics (KYMR) Valuation After Late Breaking KT-621 AAD 2026 Selection - Sahm
Kymera’s KT-621 Faces "Sell the News" Risk as AAD Data and Dilution Collide - Bitget
Jobs Data: Can Kymera Therapeutics Inc benefit from deglobalization2026 Retail & Safe Entry Point Identification - baoquankhu1.vn
Kymera Q4 loss wider than expected, cash boost extends runway - MSN
Esposito sells Kymera (KYMR) shares worth $197,877 By Investing.com - Investing.com Canada
Kymera Therapeutics (KYMR) director exercises options, sells 2,500 shares under 10b5-1 plan - Stock Titan
KYMR (KYMR) Form 144 shows option exercise and 10b5-1 sales by insider - Stock Titan
Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026 - Insider Monkey
Stock Recap: Is Kymera Therapeutics Inc currently under institutional pressure2026 Closing Moves & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Highs Report: Is now the right time to enter Kymera Therapeutics IncMarket Performance Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
(KYMR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Nextech Invest Sells $4.19M in Kymera Shares, Stake Value Rises to $21.7MNews and Statistics - IndexBox
Nextech Trims Kymera at a Recent High — think Foolishly before acting. - AOL.com
Aug Selloffs: What is the long term forecast for Kymera Therapeutics Inc stock2026 Market Sentiment & Pattern Based Trade Signal System - baoquankhu1.vn
Aug Breakouts: What is Kymera Therapeutics Incs 5 year growth outlookPortfolio Return Report & Consistent Return Strategy Ideas - baoquankhu1.vn
Weekly Earnings: Is Kymera Therapeutics Inc currently under institutional pressure2026 Price Momentum & Smart Investment Allocation Insights - baoquankhu1.vn
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kymera Therapeutics Inc-Aktie (KYMR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chadwick Jeremy G | Chief Operating Officer |
Mar 31 '26 |
Option Exercise |
29.64 |
7,600 |
225,264 |
68,802 |
| Ridloff Elena | Director |
Mar 31 '26 |
Option Exercise |
14.18 |
7,400 |
104,932 |
7,400 |
| Ridloff Elena | Director |
Apr 01 '26 |
Option Exercise |
14.18 |
4,600 |
65,228 |
4,600 |
| Chadwick Jeremy G | Chief Operating Officer |
Apr 01 '26 |
Sale |
85.46 |
14,640 |
1,251,166 |
61,202 |
| Chadwick Jeremy G | Chief Operating Officer |
Mar 31 '26 |
Sale |
85.38 |
7,600 |
648,882 |
61,202 |
| Ridloff Elena | Director |
Mar 31 '26 |
Sale |
85.37 |
7,400 |
631,739 |
0 |
| Ridloff Elena | Director |
Apr 01 '26 |
Sale |
85.42 |
4,600 |
392,922 |
0 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):